Exploring GHBP as a surrogate of GH activity in multimorbid older adults: A cross-sectional study

IF 2 4区医学 Q4 CELL BIOLOGY

Growth Hormone & Igf Research Pub Date : 2025-10-01 Epub Date: 2025-09-29 DOI:10.1016/j.ghir.2025.101666

Olivia Tausendfreund , Martin Bidlingmaier , Michael Haenelt , Tim Kuehnle , Linda Deissler , Sebastian Martini , Katharina Mueller , Michaela Rippl , Katharina Schilbach , Sabine Schluessel , Ralf Schmidmaier , Michael Drey

{"title":"Exploring GHBP as a surrogate of GH activity in multimorbid older adults: A cross-sectional study","authors":"Olivia Tausendfreund , Martin Bidlingmaier , Michael Haenelt , Tim Kuehnle , Linda Deissler , Sebastian Martini , Katharina Mueller , Michaela Rippl , Katharina Schilbach , Sabine Schluessel , Ralf Schmidmaier , Michael Drey","doi":"10.1016/j.ghir.2025.101666","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>With the rise of aging societies and complex multimorbidity, age related endocrine alterations such as insulin-like growth factor I (IGF<img>I) deficiency gain clinical importance. Beyond reduced growth hormone (GH) secretion, GH resistance represents an additional mechanism contributing to IGF-I deficiency, potentially aggravating age-related diseases.</div></div><div><h3>Purpose</h3><div>This study investigates whether multimorbid, high-aged patients with IGF-I deficiency exhibit a form of acquired peripheral GH resistance, as indicated by altered GH-binding protein (GHBP) concentrations.</div></div><div><h3>Materials and methods</h3><div>In a cross-sectional design we conducted a retrospective analysis of serum samples of 759 patients from the geriatric day clinic and acute geriatric ward of the Ludwig-Maximilians-University Hospital, Munich.</div></div><div><h3>Results</h3><div>The mean age was 81 years, with a mean baseline IGF-I of 85 ng/ml (corresponding to −0.07/−0.1 SDS in males/females), a mean GHBP concentration of 751 pM and a mean GH concentration of 1.68 ng/ml. Patients with IGF-I concentrations below 2 standard deviation score (SDS) exhibited significantly elevated GH alongside reduced GHBP, suggestive of a peripheral GH resistance (<em>n</em> = 48). In contrast, the subgroup (<em>n</em> = 26) with the highest IGF-I concentrations (up to 2 SDS), demonstrated elevated GH and high GHBP concentrations.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that low GHBP may indicate acquired peripheral GH resistance in a subset of multimorbid, high-aged patients. Further functional endocrine testing, including IGF-I generation test is necessary. Analysis of the subgroup with above-average IGF-I concentrations could provide insights into longevity and on the safety of GH and IGF-I treatment.</div></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"82 ","pages":"Article 101666"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Growth Hormone & Igf Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096637425000309","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

With the rise of aging societies and complex multimorbidity, age related endocrine alterations such as insulin-like growth factor I (IGFI) deficiency gain clinical importance. Beyond reduced growth hormone (GH) secretion, GH resistance represents an additional mechanism contributing to IGF-I deficiency, potentially aggravating age-related diseases.

Purpose

This study investigates whether multimorbid, high-aged patients with IGF-I deficiency exhibit a form of acquired peripheral GH resistance, as indicated by altered GH-binding protein (GHBP) concentrations.

Materials and methods

In a cross-sectional design we conducted a retrospective analysis of serum samples of 759 patients from the geriatric day clinic and acute geriatric ward of the Ludwig-Maximilians-University Hospital, Munich.

Results

The mean age was 81 years, with a mean baseline IGF-I of 85 ng/ml (corresponding to −0.07/−0.1 SDS in males/females), a mean GHBP concentration of 751 pM and a mean GH concentration of 1.68 ng/ml. Patients with IGF-I concentrations below 2 standard deviation score (SDS) exhibited significantly elevated GH alongside reduced GHBP, suggestive of a peripheral GH resistance (n = 48). In contrast, the subgroup (n = 26) with the highest IGF-I concentrations (up to 2 SDS), demonstrated elevated GH and high GHBP concentrations.

Conclusion

Our findings suggest that low GHBP may indicate acquired peripheral GH resistance in a subset of multimorbid, high-aged patients. Further functional endocrine testing, including IGF-I generation test is necessary. Analysis of the subgroup with above-average IGF-I concentrations could provide insights into longevity and on the safety of GH and IGF-I treatment.

查看原文本刊更多论文

探索GHBP作为多种疾病老年人生长激素活性的替代品：一项横断面研究

随着老龄化社会的兴起和复杂的多病，年龄相关的内分泌改变，如胰岛素样生长因子I （IGFI）缺乏，在临床中具有重要意义。除了生长激素（GH）分泌减少外，GH耐药性是导致IGF-I缺乏的另一种机制，可能会加重与年龄相关的疾病。目的：本研究探讨多种疾病的高龄IGF-I缺乏症患者是否表现出一种获得性外周生长激素抵抗，如GH结合蛋白（GHBP）浓度改变所表明的那样。材料和方法采用横断面设计，对慕尼黑路德维希-马克西米利安大学医院老年日间门诊和急性老年病房759例患者的血清样本进行回顾性分析。结果平均年龄81岁，平均基线IGF-I为85 ng/ml（男性/女性为- 0.07/ - 0.1 SDS），平均GHBP浓度为751 pM，平均GH浓度为1.68 ng/ml。IGF-I浓度低于2个标准差评分（SDS）的患者表现出显著的生长激素升高和GHBP降低，提示外周生长激素抵抗（n = 48）。相反，IGF-I浓度最高的亚组（n = 26）（高达2 SDS）显示GH和GHBP浓度升高。结论：我们的研究结果表明，低GHBP可能表明在多病的高龄患者中存在获得性外周生长激素抵抗。进一步的内分泌功能测试，包括IGF-I生成测试是必要的。对IGF-I浓度高于平均水平的亚组进行分析，可以深入了解生长激素和IGF-I治疗的寿命和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Growth Hormone & Igf Research 医学-内分泌学与代谢

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

57 days

期刊介绍： Growth Hormone & IGF Research is a forum for research on the regulation of growth and metabolism in humans, animals, tissues and cells. It publishes articles on all aspects of growth-promoting and growth-inhibiting hormones and factors, with particular emphasis on insulin-like growth factors (IGFs) and growth hormone. This reflects the increasing importance of growth hormone and IGFs in clinical medicine and in the treatment of diseases.